MOLECULAR PARTNERS AG MOLN 深 沪
已收盘 09-12 16:00:00 美东时间
3.72
-0.030
-0.80%
华盛通- 最 高3.74
- 今 开3.73
- 成交量 2286股
- 最 低 3.72
- 昨 收 3.75
- 总市值 1.37亿
- 52周最高 7.60
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 3.36
- 委 比 41.34%
- 总股本 3687.46万
- 历史最高 32.04
- 量 比 1.22
- 振 幅 0.53%
- 历史最低 3.32
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Looking Into Molecular Partners's Recent Short Interest
Molecular Partners's (NYSE:MOLN) short percent of float has fallen 5.56% since ...
09-04 04:00
JP Morgan Maintains Neutral on Molecular Partners, Lowers Price Target to $4
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lowers the price target from $4.5 to $4.
09-03 23:18
Moleculin Issues New Positive AML Overall Survival Data:
Moleculin Biotech announced the completion of its Phase 1B/2 MB-106 trial evaluating Annamycin in combination with Cytarabine for treating acute myeloid leukemia (AML). The trial enrolled 22 subjects, with updated overall survival (OS) data showing a median OS of 15 months for complete remission (CR) patients (n=8), 12 months for the 2L efficacy evaluable population (n=9), and 9 months for the intent-to-treat (ITT) population (n=22). These result...
08-27 12:45
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Invivyd (NASDAQ:IVVD) stock increased by 132.3% to $1.3 during Tuesday...
08-26 20:09
Molecular Partners Q2 EPS $(0.67) Down from $(0.56) YoY
Molecular Partners (NASDAQ:MOLN) Q2 EPS $(0.67) Down from $(0.56) YoY
08-26 04:06
Molecular Partners To Reduce Workforce By Up To 24%
In H1 2025, Molecular Partners undertook a strategic review of its operations and headcount, with the objectives of increased efficiency in the organization and to sharpen the focus on advancing its clinical assets. As a
08-26 04:02
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
Molecular Partners AG announced corporate highlights and financial results for H1 2025, including positive data for MP0533 in low disease burden patients, initiation of MP0712's Phase 1 trial, and the appointment of Martin Steegmaier, Ph.D., as CSO. The company reported CHF 114 million in cash as of June 2025, extending its runway into 2028.
08-25 20:00
Earnings Scheduled For August 25, 2025
Companies Reporting Before The Bell • PDD Holdings (NASDAQ:PDD) is likely to re...
08-25 16:32
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
Molecular Partners has appointed Martin Steegmaier, Ph.D., as Chief Scientific Officer (CSO), effective October 1, 2025. Martin brings extensive experience in oncology drug development, having previously led oncology programs at SOTIO Biotech, MorphoSys, Roche, and Boehringer Ingelheim. His expertise in oncology and leadership will support the company's development of DARPin therapeutics, including Radio-DARPins and Switch-DARPins for cancer trea...
08-21 05:00
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
Moleculin Biotech, Inc. appoints Adriano Treve as a Strategic Advisor to enhance partnerships and advance its Phase 2B/3 MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia (AML). With over 40 years of experience at Roche, Treve brings expertise in global healthcare and market access. Moleculin expects his insights to strengthen strategic collaborations and accelerate development of key partnerships, aiming to cr...
07-17 12:25
